Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: Drug loading and pharmacokinetic studies

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 3, 2011, Pages 376-384

  Li, ChunLei ^a,b   Cui, JingXia ^c   Wang, CaiXia ^a,b   Zhang, Lan ^a,b   Xiu, Xian ^a,b   Li, YongFeng ^a,b   Wei, Na ^a,b   Li, YanHui ^a,b   Zhang, Li ^a,b  

^a CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

^b Hebei Pharmaceutical Engineering and Technology Research Center   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cholesterol polyethylene glycol; Drug loading; Liposomes; Pharmacokinetics; Vinorelbine

Indexed keywords

CHOLESTEROL; IRINOTECAN; LIPOSOME; MACROGOL; NAVELBINE; SULFOSALICYLIC ACID; TRIETHYLAMINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; ENCAPSULATION; IN VIVO STUDY; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COATED VESICLES; DRUG CARRIERS; FLUORESCENT DYES; HALF-LIFE; LIPOSOMES; MICE; POLYETHYLENE GLYCOLS; SPECTROMETRY, FLUORESCENCE; VINBLASTINE;

EID: 79952220381     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01227.x     Document Type: Article

References (32)

1. Zhang J et al. Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. J Pharm Pharmacol 2009; 61: 1171-1178.
2. Manconia M et al. Phycocyanin liposomes for topical anti-inflammatory activity: in-vitro in-vivo studies. J Pharm Pharmacol 2009; 61: 423-430.
3. Albasarah YY et al. Chitosan-coated antifungal formulations for nebulisation. J Pharm Pharmacol 2010; 62: 821-828.
4. Drummond DC et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
5. Wu NZ et al. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res 1993; 53: 3765-3770. (Pubitemid 23252040)
6. Rentsch KM et al. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Eur J Clin Pharmacol 1998; 54: 83-89. (Pubitemid 28189405)
7. Cattel L et al. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 2003; 89: 237-249. (Pubitemid 37014112)
8. Vail DM et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567-1571. (Pubitemid 28265245)
9. Vail DM et al. Stealth liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002; 50: 131-136. (Pubitemid 34969509)
10. Toso C, Lindley C. Vinorelbine: a novel vinca alkaloid. Am J Health Syst Pharm 1995; 52: 1287-1304.
11. Gregory RK, Smith IE. Vinorelbine - a clinical review. Br J Cancer 2000; 82: 1907-1913. (Pubitemid 30326449)
12. Semple SC et al. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci 2005; 94: 1024-1038. (Pubitemid 40780769)
13. Zhigaltsev IV et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 2005; 104: 103-111. (Pubitemid 40615239)
14. Zhigaltsev IV et al. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release 2006; 110: 378-386. (Pubitemid 41829566)
15. Roth A et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 2007; 6: 2737-2746. (Pubitemid 350058154)
16. Webb MS et al. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm 2007; 65: 289-299.
17. 111In- labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med 2009; 50: 2073-2081.
18. Oussoren C et al. The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochim Biophys Acta 1998; 1369: 159-172. (Pubitemid 28129268)
19. Waterhouse DN et al. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol 2005; 391: 40-57. (Pubitemid 40254028)
20. Kenworthy AK et al. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 1995; 68: 1921-1936.
21. Vaage J et al. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer 1992; 51: 942-948.
22. Haran G et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201-215. (Pubitemid 23283973)
23. Madej A. Preparation and characterization of the double potassium salt of sulfosalicylic acid as a standard substance in alkalimetry. Microchimica Acta 1985; 85: 383-387.
24. Ickenstein LM et al. Disc formation in cholesterol-free liposomes during phase transition. Biochim Biophys Acta 2003; 1614: 135-138. (Pubitemid 36929977)
25. Mills JK, Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta 2005; 1716: 77-96. (Pubitemid 41532286)
26. Beugin S et al. New sterically stabilized vesicles based on nonionic surfactant, cholesterol, and poly(ethylene glycol)-cholesterol conjugates. Biophys J 1998; 74: 3198-3210. (Pubitemid 28268143)
27. Fanciullino R et al. Development of stealth liposome formulation of 2′-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. Pharm Res 2005; 22: 2051-2057. (Pubitemid 41821584)
28. Li C et al. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone. Int J Pharm 2008; 362: 60-66.
29. Carrion C et al. Preparation of long-circulating immunoliposomes using PEG-cholesterol conjugates: effect of the spacer arm between PEG and cholesterol on liposomal characteristics. Chem Phys Lipids 2001; 113: 97-110. (Pubitemid 33001479)
30. Ishiwata H et al. Physical chemistry characteristics and biodistribution of poly(ethylene glycol)-coated liposomes using poly(oxyethylene) cholesteryl ether. Chem Pharm Bull (Tokyo) 1995; 43: 1005-1011.
31. Sriwongsitanont S, Ueno M. Physicochemical properties of PEG-grafted liposomes. Chem Pharm Bull (Tokyo) 2002; 50: 1238-1244. (Pubitemid 41656839)
32. Yuda T et al. Prolongation of liposome circulation time by various derivatives of polyethyleneglycols. Biol Pharm Bull 1996; 19: 1347-1351. (Pubitemid 26363633)